A phase IB study of binimetinib and palbociclib in molecularly selected advanced triple-negative breast cancer.
Authors:
- Luis MansoLMLuis Manso
- Rodrigo Sánchez-BayonaRSRodrigo Sánchez-Bayona
- Juan Antonio GuerraJGJuan Antonio Guerra
- Alfonso Cortés-SalgadoACAlfonso Cortés-Salgado
- Juan Miguel. CejalvoJCJuan Miguel. Cejalvo
- Jose A. Garcia-SaenzJGJose A. Garcia-Saenz
- Serafín MoralesSMSerafín Morales
- Lucia González-CortijoLGLucia González-Cortijo
- Silvana MourónSMSilvana Mourón
- Maria J. BuenoMBMaria J. Bueno
- Leonardo D. GarmaLGLeonardo D. Garma
- Miguel Quintela-FandinoMQMiguel Quintela-Fandino
Open Access
- 10 September 2025
- journal article
- biomarkers
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 5 (9) , 1728-1737
Abstract
Purpose:Advanced, pre-treated TNBC has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that CDK6 and ERK hyperactivation are linked to adverse outcomes and represent actionable targets. This prompted us to evaluate palbociclib and binimetinib in advanced TNBC after one or two prior therapies. Patients and Methods:Patients with increased ERK and/or CDK6 activity were eligible. Treatment consisted in daily binimetinib (45 mg BID) plus palbociclib (100 mg daily, days 1-21) in 28-day cycles. Palbociclib escalation to 125 was allowed in cycle 2. The primary objective was to demonstrate a 2.5 month-long PFS, a 50% increase over the reference PFS for cytotoxics (1.7 months). Whole-exome sequence (WES) was performed in tumor samples of the efficacy population. Results:Fifty-one patients were screened, 50 were biomarker-positive. Twenty-four initiated treatment between June 2021 and July 2022. Toxicity was frequent, consisting mainly in fatigue, diarrhea, neutropenia and ocular effects, requiring frequent dose interruptions or reductions. The primary objective was not met (median PFS 50 days). However, a bimodal PFS pattern emerged, with 13% of the patients achieving disease control lasting 4-13 months. WES revealed a distinct mutational landscape among long-term responders compared to early progressors. Conclusions:In this biomarker-enriched TNBC population, the combination of palbociclib and binimetinib showed limited activity and notable toxicity. While CDK6 and ERK hyperactivation confirmed their prognostic role, they did not predict treatment benefit. Exploratory genomic findings suggest the existence of a biologically distinct subset of patients with prolonged benefit, encouraging further investigation.Keywords
All Related Versions
This publication has 41 references indexed in Scilit:
- Cochlin Produced by Follicular Dendritic Cells Promotes Antibacterial Innate ImmunityImmunity, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanomaNature Medicine, 2012
- Sequence analysis of mutations and translocations across breast cancer subtypesNature, 2012
- The clonal and mutational evolution spectrum of primary triple-negative breast cancersNature, 2012
- A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer CellsCancer Cell, 2011
- HERC2 Interacts with Claspin and Regulates DNA Origin Firing and Replication Fork ProgressionCancer Research, 2011
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Research, 2009
- 1000 Genomes projectNature Biotechnology, 2008